As the regulatory agencies and pharmaco-economic pressures increasingly call for more effective drugs, we believe that personalized or targeted medicines represent the next generation of pharmaceutical treatment.

At Curidium, we have set out to fully exploit our PsychINDx™ diagnostic tool and core Homomatrix^® technology to develop, in partnership with pharmaceutical and biotechnology companies, targeted medicines for specific patient subgroups for a range of heterogeneous human diseases, including schizophrenia and bipolar disorder.